By regulating the PPAR δ-AMPK-PGC-1 α pathway in dyslipidemic conditions, aspirin, and PPAR-α activators improve nonalcoholic fatty liver disease and atherosclerosis. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.